Design and fabrication of a 5-fluorouracil-based nanocarrier containing carboxymethyl cellulose/ riboflavin/ carbon nanotubes for delivery to MCF-7 cancer cells
The primary objective of this research is to develop a highly stable, biocompatible nanocomposite for pH-responsive, controlled delivery of 5-fluorouracil (5-FU) to enhance its therapeutic performance. In this study, a carboxymethyl cellulose (CMC)/ riboflavin (RF) /carbon nanotubes (CNTs)-based nanocomposite was synthesized using the water/oil/water (W/O/W) double emulsion method with the aid of sweet almond oil and the surfactant Span 80, for controlled delivery of the drug 5-FU. Fourier-transform infrared spectroscopy (FTIR) was used to examine the functional groups of the nanocomposite components, and X-ray diffraction (XRD) was used to study the crystal structure. To determine the morphology, a field-emission scanning electron microscope (FE-SEM) was used, which confirmed the core-shell structure of the nanocarriers with a hemispherical shape. Dynamic light scattering (DLS) was used to determine the particle size, which was reported to be 236.7 nm. Analysis of zeta potential showed a value of −89.77 ± 3.20 mV, indicating a highly stable colloidal structure. The drug loading efficiency (LE) was 45.25%, and the encapsulation efficiency (EE) was 87%. Over a 96-hour period, the drug-loaded nanocarrier exhibited a strictly pH-dependent behavior, with cumulative drug release reaching a maximum of 91% in the acidic tumor environment (pH 5.4) versus 75% in the neutral healthy tissue medium (pH 7.4). The drug release mechanism was investigated by fitting experimental data to different kinetic models. The release patterns of 5-FU in the nanocomposite under neutral and acidic conditions followed the Hixson-Crowell ( 𝑅 2 = 0 . 9 9 7 2 ) and Korsmeyer–Peppas ( 𝑅 2 = 0 . 9 6 1 9 ) kinetic models, respectively. The MTT assay was performed to assess cell viability and cytotoxicity, revealing that the CNTs/CMC/RF@5-FU nanocarrier exhibited significant cytotoxicity against breast cancer cells, successfully reducing MCF-7 cell viability to 35.45% compared to 50.51% for the free drug.
Authors
- Fatemeh Askari Yazdian (ORCID: https://orcid.org/0000-0002-0550-9821)
- Hamid Rashedi (ORCID: https://orcid.org/0000-0002-8460-0841)
- Mehrab Pourmadadi (ORCID: https://orcid.org/0000-0002-8819-3649)
- Nassrin Qavami
- Mobina Momeni
Institutions
- University of Tehran (IR)
- Academic Center for Education, Culture and Research (IR)
- Shahid Beheshti University (IR)
Publication Details
- Journal
- Next Nanotechnology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.nxnano.2026.100931
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00